Streetwise Reports

The Gold Report

The Energy Report

The Life Sciences Report

Streetwise Reports

The Gold Report

The Energy Report

Trending Now

Dental & Animal Health Supplier Posts 10% Yearly Sales Gains

(06/29/2022)

Dental & Animal Health Supplier Posts 10% Yearly Sales Gains

Shares of Patterson Companies Inc. traded 11% higher after the dental supply and animal health products distributor reported Q4/22 and FY/22 financial results highlighting a 9.9% increase in annual sales and an expansion in operating margins.

Tags: NutraceuticalsHealthcare Services

New Alzheimer's Drug Shows Promise as Monotherapy

Research Report

(06/29/2022)

New Alzheimer's Drug Shows Promise as Monotherapy

Athira Pharma Inc.'s treatment with this small molecule alone resulted in improvements related to both primary and secondary endpoints, indicating pharmacological activity, noted a BTIG report.

Tags: Biotechnology / Pharmaceuticals

Small Cap Joins with Japan Pharma to Advance Next Generation Cancer Treatment

(06/28/2022)

Small Cap Joins with Japan Pharma to Advance Next Generation Cancer Treatment

Shares of Sutro Biopharma Inc. traded 21% higher after the company announced it entered into a global collaboration agreement with Japan's Astellas Pharma to advance three novel immunostimulatory antibody-drug conjugates.

Tags: Biotechnology / Pharmaceuticals

Drug Co. to Conduct P1/2a Trial of Psilocybin in Depression

Research Report

(06/27/2022)

Drug Co. to Conduct P1/2a Trial of Psilocybin in Depression

In this trial, slated to commence next quarter, the biopharma will test the efficacy of its version of the psychedelic compound in this mental health indication, noted a ROTH Capital Partners report.

Tags: Psychedelics

Approval Likely of New Gel for Skin Condition, Analyst Says

Research Report

(06/27/2022)

Approval Likely of New Gel for Skin Condition, Analyst Says

The biotech developer of this gene therapy is preparing to launch it commercially in the U.S. and pursuing approval of it elsewhere in the world, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

EU Biopharma Co. Makes $247M Bid for US Oncology Co.

Streetwise Reports (06/27/2022)

EU Biopharma Co. Makes $247M Bid for US Oncology Co.

Epizyme Inc. shares traded 55% higher today after the company reported that it agreed to be acquired by Ipsen S.A. of France for $1.45 per share along with a contingent value right of $1.00 per share.

Tags: Biotechnology / Pharmaceuticals

Gene Therapy Co. Releases Data From Huntington's Study

Streetwise Reports (06/23/2022)

Gene Therapy Co. Releases Data From Huntington's Study

Shares of uniQure N.V. traded 26% higher after the company released 12-month treatment data from the low-dose cohort in its Phase 1/2 Huntington's disease clinical trial.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co. Doses First MM Patient in Ph. 1 Leukemia Trial

Streetwise Reports (06/22/2022)

Biopharma Co. Doses First MM Patient in Ph. 1 Leukemia Trial

Shares of Biomea Fusion Inc. traded 14% higher after the company reported it dosed the first Multiple Myeloma patient in its Phase 1 COVALENT-101 r/r acute leukemia trial.

Tags: Biotechnology / Pharmaceuticals

PE Firm to Take Health Tech Co. Private in $1.1B Deal

Streetwise Reports (06/22/2022)

PE Firm to Take Health Tech Co. Private in $1.1B Deal

Shares of healthcare technology and services firm Convey Health Solutions Holdings Inc. traded 138% higher after the company reported it received a proposal from majority shareholder TPG Inc. to take the company private. TPG has offered to buy all outstanding shares in Convey that it does not already own for $10.50 per share in cash.

Tags: TechnologyHealthcare Services

Results of Dermatitis Clinical Trial Due This Summer

Research Report

(06/21/2022)

Results of Dermatitis Clinical Trial Due This Summer

Enrollment is now done for VYNE Therapeutics Inc.'s Phase 2a trial following encouraging Phase 1b efficacy data, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

New Positive Data Seem to Support Drug Label Expansion

Research Report

(06/21/2022)

New Positive Data Seem to Support Drug Label Expansion

Checkpoint Therapeutics Inc., the biopharma behind this late-stage monoclonal antibody for metastatic cutaneous squamous cell carcinoma, could use the new trial results to seek approval in the locally advanced presentation of this cancer, too, noted a Ladenburg Thalmann report.

Tags: Biotechnology / Pharmaceuticals

New Drug for Heart Failure on Path to Approval, Analyst Says

Research Report

(06/20/2022)

New Drug for Heart Failure on Path to Approval, Analyst Says

The U.S. Food and Drug Administration will likely approve Cytokinetics Inc.'s small molecule in Q1/23, during which its PDUFA date is scheduled, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

NFL Player Teams With Biopharma Co. to Help SCD Patients

Streetwise Reports (06/17/2022)

NFL Player Teams With Biopharma Co. to Help SCD Patients

Shares of Global Blood Therapeutics Inc. traded 12% higher after the company reported it has teamed up with New York Jets running back Tevin Coleman and his family to promote education and to offer hope and support to families affected by sickle cell disease.

Tags: Biotechnology / Pharmaceuticals

Biotech Co. Advances 3 New Clinical Stage Assets

Research Report

(06/16/2022)

Biotech Co. Advances 3 New Clinical Stage Assets

Ocugen Inc.'s new diverse product candidates include a COVID vaccine, a gene therapeutic for retinitis pigmentosa, and a cell therapy to prevent osteoarthritis, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

Dispute Between Biopharma Cos. To Be Resolved by Sept. 30

Research Report

(06/16/2022)

Dispute Between Biopharma Cos. To Be Resolved by Sept. 30

The arbitration court extended the original deadline for a decision in this case of an alleged breach of contract between TRACON Pharmaceuticals Inc. and I-Mab Biopharma, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Expert Investing Ideas

"RHT is showing strong earnings quality and cash flow quality."

–Jefferson Research

"AGN looks like it is shaping up for a breakout into a new bull market."

–Clive Maund, CliveMaund.com

"We are initiating coverage on PMN with a Speculative Buy rating."

–Douglas Loe, Leede Jones Gable

"RHT is rated an Immediate Buy here."

–Clive Maund, CliveMaund.com

"We view PMN's path to clinical value inflection favorably."

–Steve Silver, Argus Research

"AGN has reacted back satisfactorily to another good buy spot."

–Clive Maund, CliveMaund.com

"AGN's current valuation is favorable from a risk-reward standpoint."

–André Uddin, Research Capital Corporation

"As we can see on its latest six-month chart, AGN's stock has soared."

–Clive Maund, CliveMaund.com

"AGN has a lot of potential, and I placed my bet with shares bought."

–Bob Moriarty, 321 Gold

"After a 1 for 100 rollback, AGN has big upside potential."

–Clive Maund, CliveMaund.com

"AGN stock looks like it is in the process of turning up from a low."

–Clive Maund, CliveMaund.com

"We could soon see some good gains in AGN."

–Clive Maund, CliveMaund.com

"AGN's risk/reward profile is attractive."

–André Uddin, Research Capital Corporation

"RTG's vigorous uptrend is probably targeting the CA$1.30–1.40 area."

–Clive Maund, CliveMaund.com

"AGN is switching focus to the IPF/chronic cough indication."

–André Uddin, Research Capital Corporation

"AGN received positive FDA feedback on its planned Phase 1 trial."

–Sam Riches, Weekend Dispensary

"AGN requested a meeting with the FDA to discuss advancing ifenprodil."

–André Uddin, Research Capital Corporation

"Final results from AGN's Phase 2b COVID-19 trial are expected soon."

–André Uddin, Research Capital Corporation

"AGN is to continue a number of preclinical studies of DMT for stroke."

–André Uddin, Research Capital Corporation

"AGN is starting clinical research with a psychedelic drug for stroke."

–Clive Maund, CliveMaund.com

More News APP:CSE; FUAPF:OTCQB; 2FA:FSA | PMN:TSX; ARFXF:OTCQB | SRTS:NASDAQ

Company News

RHT:TSX.V; RQHTF:OTCQB; A2AJTB:WKN
6/28/2022 – Reliq Health Technologies, Inc. Announces Six New US Contracts and New In-Facility RPM Programs

PMN:TSX; ARFXF:OTCQB
6/27/2022 – PROMIS ANNOUNCES REVERSE SHARE SPLIT TO MEET NASDAQ LISTING CRITERIA

AGN:CSE; AGNPF:OTCQB; AGN0:XFRA
6/27/2022 – Algernon Pharmaceuticals Announces Pricing of Public Offering of Units

PMN:TSX; ARFXF:OTCQB
6/22/2022 – ProMIS Neurosciences Announces Authorization of Series 1 Preferred Shares

PMN:TSX; ARFXF:OTCQB
6/22/2022 – ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application

PMN:TSX; ARFXF:OTCQB
6/22/2022 – ProMIS Neurosciences Announces Debt Amendment and Conversion

AGN:CSE; AGNPF:OTCQB; AGN0:XFRA
6/22/2022 – Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

Tune In to Our NEW Podcast: Streetwise Listens

NASDAQ Biotech ARCA Pharmaceutical

Healthcare Tech Firm Improves Earnings and Cash Flow in Q3/22

Research Report

(06/14/2022)

Healthcare Tech Firm Improves Earnings and Cash Flow in Q3/22

These changes earned Reliq Health Technologies Inc. an upgrade in overall rating by independent investment research and advisory firm, Jefferson Research.

Tags: Healthcare Services

Investors Gain a Breath of Fresh Air From Ph. 3 CS Trial Results

Streetwise Reports (06/13/2022)

Investors Gain a Breath of Fresh Air From Ph. 3 CS Trial Results

Optinose Inc. shares traded 40% higher after the company reported positive top-line data from its Phase 3 ReOpen2 Trial of XHANCE for use in treating chronic sinusitis without nasal polyps.

Tags: Biotechnology / Pharmaceuticals

Biotech Co.'s Shares Soar on Ph. 2 Hematology Trial Results

Streetwise Reports (06/10/2022)

Biotech Co.'s Shares Soar on Ph. 2 Hematology Trial Results

Cogent Biosciences Inc. shares traded 70% higher after the firm reported positive clinical data from Part 1 of its ongoing Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM), a severe hematologic disorder.

Tags: Biotechnology / Pharmaceuticals

New Drug for Peanut Allergy in Toddlers Shown Safe and Effective

Research Report

(06/10/2022)

New Drug for Peanut Allergy in Toddlers Shown Safe and Effective

The response rate to DBV Technologies SA's drug patch in the recent Phase 3 clinical trial was statistically significant, which bodes well for the company as there is currently no approved therapy for children with this condition.

Tags: Biotechnology / Pharmaceuticals

Biopharma Co.'s New Diabetes Drug Candidate Shows Promise

Research Report

(06/10/2022)

Biopharma Co.'s New Diabetes Drug Candidate Shows Promise

Biomea Fusion Inc.'s new menin inhibitor is soon to begin clinical human trials after it restored glycemic control and outperformed the standard of care, in animal models.

Tags: Biotechnology / Pharmaceuticals

Good Chance FDA Will Greenlight Solution for Dry Eye Disease

Research Report

(06/09/2022)

Good Chance FDA Will Greenlight Solution for Dry Eye Disease

Approval would be positive news for Aldeyra Therapeutics Inc. given the market for the indication is large and underserved, noted a BTIG report.

Tags: Biotechnology / Pharmaceuticals